Allergan Receives FDA Approval of TEFLARO(R) (ceftaroline fosamil) for Pediatric Patients
Label Now Includes New Data on Use of TEFLARO in Pediatric Patients 2 Months of Age to Less than 18 Years of Age with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP)
TEFLARO is the First Bran... Biopharmaceuticals, FDAAllergan, ABSSSI, TEFLARO, MRSA
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Allergy | Bacterial Pneumonia | Infectious Diseases | MRSA | Pediatrics | Pharmaceuticals | Pneumonia | Skin | Superbugs